Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P220032/S012

POLARx and POLARx Cryoablation Balloon Catheters; POLARSHEATH Steerable Sheaths; SMARTFREEZE Cryoablation System Console

BOSTON SCIENTIFIC CORPORATION · Decision date May 29, 2026

FDA DECISIONP220032/S012

What did the FDA approve?

FDA records P220032/S012 as a supplement to PMA P220032, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated May 29, 2026.

FDA approval order statement

Approval to amend the PAS protocol to terminate enrollment, discontinue all protocol-required follow-up beyond the 3-month visit, and conduct an analysis of all available data collected to date
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Cardiovascular
Decision date
May 29, 2026
FDA change category
Postapproval Study Protocol

FDA source record

Regulatory record facts

Identifier
P220032/S012
Regulatory pathway
PMA supplement
Product code
OAE
Decision code
APPR
Decision date
May 29, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Catheter, percutaneous, cardiac ablation, for treatment of atrial fibrillation.

Product code
OAE
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P220032/S011 · Related supplement

    POLARx Cryoablation System

  2. P220032/S012 received

    Application receipt date recorded by FDA.

  3. P220032/S012 · FDA decision

    Normal 180 Day Track No User Fee

Timeline entries are records held by MedtechLedger for P220032. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P220032

Product / regulatory recordCompanyPathwayDecision dateSource
BOSTON SCIENTIFIC CORPORATIONPMA supplementAug 14, 2025FDA

Explore the linked device profile

Other records with product code OAE

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Boston Scientific Corporation

Headquarters
Not reported
FDA applicant address
4100 Hamline Ave. N, St Paul, MN, 55112

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records